Novo Nordisk turns to Evotec to build early-stage pipeline for diabetes, obesity drugs

The European discovery outfit at Evotec has signed up another major league player in biopharma, and they’re prepping an early-stage pipeline right where their partner is most carefully focused.

Novo Nordisk is stepping up to work with Evotec this time. The scientists at Evotec will go to work building a preclinical pipeline of small molecules primarily concentrating on diabetes and obesity — where Novo makes its money and plans to expand. And NASH, cardiovascular diseases and diabetic kidney disease are all on the menu.

The statement on the alliance comes without any of the financial particulars. But Evotec is adding a major partnership on top of a string of deals with companies like Celgene, Bayer and Sanofi — as well as a slew of smaller biotech pacts.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->